Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alfa + elebsiran
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegylated interferon alfa + elebsiran is an investigational combination therapy being evaluated for the treatment of chronic hepatitis B virus (HBV) infection, with the goal of achieving a functional cure. The combination consists of elebsiran (VIR-2218 / BRII-835), a GalNAc-conjugated small interfering RNA (siRNA) that targets a highly conserved region of the HBV genome to degrade viral transcripts and reduce the production of hepatitis B surface antigen (HBsAg), and pegylated interferon alfa (specifically pegylated interferon alfa-2a), a long-acting recombinant interferon that stimulates the host's innate antiviral immune response. By combining siRNA-mediated viral antigen knockdown with interferon-driven immunomodulation, the therapy aims to overcome HBV-induced immune tolerance and restore effective immune control. The combination is being developed by Vir Biotechnology and Brii Biosciences, and has demonstrated promising rates of HBsAg seroclearance in Phase 2 clinical trials.
- Other names
- BRII-835 + PEG-IFNαBRII-835 + PEG-interferon-alphaBRII-835 + peginterferon alfaBRII-835 + peginterferon alfa-2aelebsiran + PEG-IFNαelebsiran + peginterferon alfa-2aelebsiran + pegylated interferon alfa-2aVIR-2218 + PEG-IFNαVIR-2218 + PEG-interferon-alphaVIR-2218 + peginterferon alfaVIR-2218 + peginterferon alfa-2aVIR-2218 + pegylated interferon alfa-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on pegylated interferon alfa + elebsiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alfa + elebsiran.